Bridging CGRP Antibodies With Gepants: Innovative Combined Migraine Approach

Novel approach combining CGRP monoclonal antibodies with gepant small molecules offers innovative migraine management strategy using both drug classes synergistically.

Alsaadi, Taoufik et al.·Clinical neurology and neurosurgery·2025·Moderate Evidencecohort
RPEP-09904CohortModerate Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
cohort
Evidence
Moderate Evidence
Sample
N=medium
Participants
Migraine patients on CGRP monoclonal antibodies experiencing wearing-off symptoms

What This Study Found

Novel approach combining CGRP monoclonal antibodies with gepant small molecules offers innovative migraine management strategy using both drug classes synergistically.

Key Numbers

24-month follow-up across 16 clinic visits evaluating combined CGRP mAb and gepant therapy.

How They Did This

In publication.

Why This Research Matters

Relevant to peptide therapeutics.

The Bigger Picture

Advances peptide therapeutic knowledge.

What This Study Doesn't Tell Us

In publication.

Questions This Raises

  • ?Long-term implications?
  • ?Comparison to evidence?
  • ?Next research?

Trust & Context

Key Stat:
Key finding Novel approach combining CGRP monoclonal antibodies with gepant small molecules offers innovative mi
Evidence Grade:
Based on study design.
Study Age:
Published in 2025.
Original Title:
Bridging CGRP mAbs with Gepants: An innovative approach to address the wearing-off phenomenon.
Published In:
Clinical neurology and neurosurgery, 258, 109183 (2025)
Database ID:
RPEP-09904

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What does this mean?

Novel approach combining CGRP monoclonal antibodies with gepant small molecules offers innovative migraine management strategy using both drug classes synergistically.

How reliable?

Consult publication.

Read More on RethinkPeptides

Cite This Study

RPEP-09904·https://rethinkpeptides.com/research/RPEP-09904

APA

Alsaadi, Taoufik; Adel, Fatema; Alsaffarini, Kareem; El Jadam, Caline; Alkhateri, Athra; Pagdato, Beverly; Suliman, Reem. (2025). Bridging CGRP mAbs with Gepants: An innovative approach to address the wearing-off phenomenon.. Clinical neurology and neurosurgery, 258, 109183. https://doi.org/10.1016/j.clineuro.2025.109183

MLA

Alsaadi, Taoufik, et al. "Bridging CGRP mAbs with Gepants: An innovative approach to address the wearing-off phenomenon.." Clinical neurology and neurosurgery, 2025. https://doi.org/10.1016/j.clineuro.2025.109183

RethinkPeptides

RethinkPeptides Research Database. "Bridging CGRP mAbs with Gepants: An innovative approach to a..." RPEP-09904. Retrieved from https://rethinkpeptides.com/research/alsaadi-2025-bridging-cgrp-mabs-with

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.